Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of “Buy” by Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned an average recommendation of “Buy” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $17.00.

A number of research analysts have recently commented on VYGR shares. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Wedbush began coverage on shares of Voyager Therapeutics in a research note on Friday, November 29th. They set an “outperform” rating and a $11.00 target price on the stock. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective on the stock.

Insider Buying and Selling

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Great Point Partners LLC purchased a new stake in shares of Voyager Therapeutics during the second quarter worth $12,668,000. Erste Asset Management GmbH acquired a new position in Voyager Therapeutics in the 3rd quarter worth about $6,192,000. Armistice Capital LLC raised its stake in shares of Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Voyager Therapeutics by 32.4% during the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after buying an additional 249,659 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at approximately $1,012,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Trading Up 3.3 %

NASDAQ VYGR opened at $6.48 on Tuesday. The company has a 50-day moving average price of $6.58 and a two-hundred day moving average price of $7.14. Voyager Therapeutics has a 52 week low of $5.19 and a 52 week high of $11.72. The stock has a market cap of $354.00 million, a price-to-earnings ratio of 9.13 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the company posted ($0.59) EPS. As a group, equities research analysts expect that Voyager Therapeutics will post -0.89 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.